Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform the market in the next 30 days [3][4] - Each stock is rated from A to F, with A indicating the highest potential for outperformance [4] Categories of Style Scores - Value Score: Focuses on identifying undervalued stocks using ratios like P/E and Price/Sales [5] - Growth Score: Evaluates a company's financial health and future growth potential through earnings and sales projections [6] - Momentum Score: Assesses trends in stock prices and earnings estimates to identify favorable investment opportunities [7] - VGM Score: Combines all three Style Scores to highlight stocks with attractive value, growth forecasts, and momentum [8] Zacks Rank and Earnings Estimates - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors in building successful portfolios [9] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [10] - There are over 800 stocks rated 1 or 2, which can be overwhelming for investors [11] Investment Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [12] - The direction of earnings estimate revisions is crucial; stocks with lower ranks but high Style Scores may still face price declines [13] Company Spotlight: Catalyst Pharmaceuticals - Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on therapies for rare diseases [14] - Currently rated 3 (Hold) with a VGM Score of A and a Value Style Score of B, indicating attractive valuation metrics [15] - The company has seen upward revisions in earnings estimates, with a Zacks Consensus Estimate of $2 per share for fiscal 2024 [15] - With a solid Zacks Rank and strong Style Scores, Catalyst Pharmaceuticals is recommended for investors' consideration [16]